Kalos Management’s Agile Therapeutics AGRX Stock Holding History

Kalos Management’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8	Closed	-$3K	–	171
2022 Q1	$3K	Buy	+8	New	+$5.11K	﹤0.01%	175
2021 Q4	–	Sell	-9	Closed	-$15K	–	291
2021 Q3	$15K	Sell	9 -1	-10%	-$2.26K	﹤0.01%	292
2021 Q2	$24K	Hold	10	–	–	0.01%	263
2021 Q1	$35K	Hold	10	–	–	0.01%	293
2020 Q4	$55K	Hold	10	–	–	0.02%	246
2020 Q3	$58K	Sell	10 -1	-9%	-$5.73K	0.03%	226
2020 Q2	$58K	Hold	11	–	–	0.02%	209
2020 Q1	$42K	Buy	+11	New	+$63.1K	0.02%	199
2019 Q4	–	Sell	-9	Closed	-$21K	–	228
2019 Q3	$21K	Buy	+9	New	+$22.2K	0.01%	196

Other funds holding AGRX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Kalos Management's AGRX Position: Q2 2022 in Review

Kalos Management sold out of Agile Therapeutics (AGRX) in Q2 2022, closing a stake of 8 shares — an estimated $3K sold.

Kalos Management first reported a position in AGRX in Q3 2019 and held it in 9 quarters. The position peaked at $58K in Q3 2020. 19 funds tracked by Wall St. Rank hold AGRX as of Q2 2022.

Kalos Management reported no remaining Agile Therapeutics position as of Q2 2022 after selling out during the quarter.
Kalos Management sold 8 Agile Therapeutics shares in Q2 2022, an estimated $3K.
Kalos Management first reported a position in Agile Therapeutics in Q3 2019 and held it in 9 quarters.
Kalos Management's Agile Therapeutics position peaked at $58K in Q3 2020.
19 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2022.

Based on Kalos Management's 13F filing for Q2 2022, filed 12 Aug 2022.